As Annex 16 Revision Proceeds, QPs Urged to Focus on Quality Systems in Certifying Batches
This article was originally published in The Gold Sheet
Qualified persons should respond to the complexities of globalization by leveraging quality systems rather than confirming every detail, Pfizer official says. Proposed revision to Annex 16 of EU GMPs defines numerous tasks QPs can delegate.
You may also be interested in...
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.
FDA historically has based 100% of drug adulteration warning letters on inspections but COVID-19-related travel restrictions began changing that in FY 2020, when 2% of drug GMP warning letters were based on testing import samples. The change became even more pronounced in the first two months of FY 2021, with 59% of actions related to sample testing and 41% to inspections.
Government offers help securing supplies in return for another 100 million doses by Q2. That would mean abandoning Pfizer’s preferred arms-length relationship.